Lupin’s Nagpur injectable facility receives EIR from USFDA

17 Feb 2023 , 10:43 AM

Lupin Limited (Lupin) announced today that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its new injectable facility in Nagpur, India.

The EIR was issued following the facility’s most recent inspection, which took place between October 17, 2022, and October 29, 2022.

‘We are delighted to announce that the USFDA has granted the EIR for our injectable facility in Nagpur,’ stated Nilesh Gupta, Lupin’s Managing Director.

‘Our state-of-the-art injectable facility in Nagpur is constructed with the purpose of meeting the most rigorous quality standards and adhering to global regulations through the incorporation of advanced technology and state-of-the-art equipment. We are dedicated to providing a significant line of injectables that tackle unfulfilled requirements from this facility,’ he added.

At around 10.32 AM, Lupin was trading 0.42% lower at Rs678.90, against the previous close of Rs681.75 on NSE. The counter touched an intraday high and low of Rs687.45 and Rs674.10 respectively.

For feedback and suggestions, write to us at [e-mail]